Trial Profile

Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Pentostatin (Primary) ; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
Indications Sickle cell anaemia
Focus Adverse reactions; Therapeutic Use

05 Mar 2026 Planned End Date changed from 18 Feb 2026 to 25 Jan 2027.
05 Mar 2026 Planned primary completion date changed from 18 Feb 2026 to 25 Jan 2027.
23 Apr 2025 Planned End Date changed from 7 Mar 2025 to 18 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com